Skip to search formSkip to main contentSkip to account menu

Fraxiparin

Known as: Fraxiparine 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Nadroparin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism
Low molecular weight heparin (LMWH) improving the cancer survival has been attracting attention for many years. Our previous… 
2002
2002
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
2000
2000
Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population.
INTRODUCTION The aims of this paper were to study the incidence of deep vein thrombosis following total knee replacement in an… 
1999
1999
Spontaneous suprachoroidal haemorrhage in a patient receiving low-molecular-weight heparin (fraxiparine) therapy.
Spontaneous suprachoroidal bleeding is a rare event. Of the six previously reported cases, five had identifiable mechanisms for… 
1998
1998
Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
1996
1996
low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin‐induced platelet shape change and does not enhance spontaneous platelet aggregation
Therapeutic concentrations, added in vitro, of a low molecular weight heparin (LMWH), nadroparin (Fraxiparine), inhibit thrombin… 
1995
1995
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser.
1994
1994
Fraxiparin, a low‐molecular‐weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice
Summary. The effect of a low‐molecular‐weight heparin, faxiparin (Nadroparinŕ;), on murine megakaryocytopoiesis in vitro and in… 
Review
1992
Review
1992
Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Pharmacokinetic investigations on Orgaran (Org 10172) have been conducted by monitoring the following biological effects: plasma… 
1990
1990
The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)